Abstract
Adoptive immunotherapy transferring cancer cell-specific cytotoxic T lymphocytes (CTLs） is expected as an ideal cancer treatment strategy that is effective not only for the regression of primary cancer but also for the suppression of metastasis and recurrence. However, the inability to prepare CTLs quantitatively and qualitatively enough for treatment and the poor accumulation of transferred CTLs in tumor limit the clinical application. Developed as a breakthrough measure is the next-generation adoptive immunotherapy using chimeric antigen receptor (CAR）-expressing T cells, and the research and development for practical use are accelerated by several reports about the dramatic clinical efficacy of CAR-T cell therapy against hematological cancers. Herein, we outline the trends and problems of research on CAR-T cell therapy and introduce our tumor vessel-injuring CAR-T cell therapy.
